Citadel Advisors’s Pacira BioSciences PCRX Stock Holding History

Citadel Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,400	Closed	-$502K	–	13899
2025 Q4	$502K	Sell	19,400 -22,600	-54%	-$537K	﹤0.01%	9006
2025 Q3	$1.08M	Buy	42,000 +23,400	+126%	+$575K	﹤0.01%	7369
2025 Q2	$445K	Sell	18,600 -3,700	-17%	-$93.3K	﹤0.01%	8918
2025 Q1	$554K	Sell	22,300 -9,000	-29%	-$215K	﹤0.01%	8259
2024 Q4	$590K	Sell	31,300 -74,200	-70%	-$1.3M	﹤0.01%	8190
2024 Q3	$1.59M	Buy	105,500 +64,500	+157%	+$1.1M	﹤0.01%	5942
2024 Q2	$1.17M	Buy	41,000 +12,900	+46%	+$367K	﹤0.01%	6280
2024 Q1	$821K	Buy	28,100 +2,800	+11%	+$86K	﹤0.01%	7351
2023 Q4	$854K	Buy	25,300 +23,100	+1,050%	+$676K	﹤0.01%	6988
2023 Q3	$67.5K	Sell	2,200 -4,900	-69%	-$177K	﹤0.01%	11376
2023 Q2	$284K	Sell	7,100 -8,500	-54%	-$351K	﹤0.01%	9168
2023 Q1	$637K	Sell	15,600 -500	-3%	-$19.9K	﹤0.01%	7803
2022 Q4	$622K	Sell	16,100 -8,700	-35%	-$423K	﹤0.01%	7791
2022 Q3	$1.32M	Buy	24,800 +16,400	+195%	+$912K	﹤0.01%	6408
2022 Q2	$490K	Sell	8,400 -7,300	-46%	-$478K	﹤0.01%	8702
2022 Q1	$1.2M	Buy	15,700 +6,400	+69%	+$427K	﹤0.01%	7292
2021 Q4	$560K	Sell	9,300 -2,400	-21%	-$132K	﹤0.01%	9418
2021 Q3	$655K	Sell	11,700 -30,000	-72%	-$1.73M	﹤0.01%	9233
2021 Q2	$2.53M	Sell	41,700 -12,800	-23%	-$810K	﹤0.01%	6011
2021 Q1	$3.82M	Buy	54,500 +21,100	+63%	+$1.51M	﹤0.01%	4877
2020 Q4	$2M	Buy	33,400 +12,700	+61%	+$744K	﹤0.01%	5359
2020 Q3	$1.24M	Sell	20,700 -10,000	-33%	-$581K	﹤0.01%	5636
2020 Q2	$1.61M	Sell	30,700 -5,900	-16%	-$247K	﹤0.01%	4940
2020 Q1	$1.23M	Buy	36,600 +8,200	+29%	+$341K	﹤0.01%	4958
2019 Q4	$1.29M	Buy	28,400 +1,900	+7%	+$80.7K	﹤0.01%	5140
2019 Q3	$1.01M	Sell	26,500 -3,400	-11%	-$136K	﹤0.01%	5579
2019 Q2	$1.3M	Sell	29,900 -900	-3%	-$38.2K	﹤0.01%	5273
2019 Q1	$1.17M	Sell	30,800 -18,100	-37%	-$706K	﹤0.01%	5312
2018 Q4	$2.1M	Buy	48,900 +14,600	+43%	+$681K	﹤0.01%	4067
2018 Q3	$1.69M	Buy	34,300 +400	+1%	+$17.3K	﹤0.01%	4680
2018 Q2	$1.09M	Buy	33,900 +2,100	+7%	+$72.5K	﹤0.01%	5068
2018 Q1	$991K	Buy	31,800 +3,800	+14%	+$135K	﹤0.01%	4822
2017 Q4	$1.28M	Sell	28,000 -3,200	-10%	-$127K	﹤0.01%	4294
2017 Q3	$1.17M	Buy	31,200 +400	+1%	+$16.1K	﹤0.01%	4091
2017 Q2	$1.47M	Sell	30,800 -6,200	-17%	-$288K	﹤0.01%	3564
2017 Q1	$1.69M	Buy	37,000 +19,100	+107%	+$826K	﹤0.01%	3266
2016 Q4	$578K	Sell	17,900 -2,100	-11%	-$70.1K	﹤0.01%	4680
2016 Q3	$684K	Buy	20,000 +6,500	+48%	+$255K	﹤0.01%	4367
2016 Q2	$455K	Sell	13,500 -34,200	-72%	-$1.68M	﹤0.01%	4621
2016 Q1	$2.53M	Buy	47,700 +14,600	+44%	+$854K	﹤0.01%	2418
2015 Q4	$2.54M	Buy	33,100 +9,000	+37%	+$510K	﹤0.01%	2503
2015 Q3	$991K	Sell	24,100 -32,900	-58%	-$2.02M	﹤0.01%	3834
2015 Q2	$4.03M	Buy	57,000 +37,900	+198%	+$2.98M	﹤0.01%	2261
2015 Q1	$1.7M	Sell	19,100 -27,100	-59%	-$2.75M	﹤0.01%	3279
2014 Q4	$4.1M	Buy	46,200 +16,700	+57%	+$1.58M	﹤0.01%	2162
2014 Q3	$2.86M	Sell	29,500 -3,700	-11%	-$360K	﹤0.01%	2499
2014 Q2	$3.05M	Buy	+33,200	New	+$2.53M	﹤0.01%	2320

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's PCRX Position: Q1 2026 in Review

Citadel Advisors reduced its Pacira BioSciences (PCRX) stake by 2.7% in Q1 2026, selling an estimated $500K and leaving 797,281 shares worth $18M. The position accounts for ﹤0.01% of the portfolio, ranked #2450.

Citadel Advisors first reported a position in PCRX in Q2 2013 and has held it in 48 quarters since. The position peaked at $44.8M in Q3 2016. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Citadel Advisors held 797,281 shares of Pacira BioSciences worth $18M as of Q1 2026.
Citadel Advisors sold 22,487 Pacira BioSciences shares in Q1 2026, an estimated $500K.
Pacira BioSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2450 holding.
Citadel Advisors first reported a position in Pacira BioSciences in Q2 2013 and has held it in 48 quarters since.
Citadel Advisors's Pacira BioSciences position peaked at $44.8M in Q3 2016.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.